China Resources Pharmaceutical Group Limited (03320.HK) announced key audited figures for its 28.00%-owned subsidiary Tasly Pharmaceutical Group Co., Ltd. for the year ended 31 December 2025.

Revenue and Earnings • Revenue fell 3.08% year-on-year to RMB8.24 billion, primarily reflecting softer sales momentum versus 2024’s RMB8.50 billion. • Net profit attributable to shareholders rose 15.63% to RMB1.10 billion, translating into basic and diluted earnings per share of RMB0.74. • Excluding extraordinary items, net profit declined 23.59% to RMB0.79 billion, indicating a sizeable non-recurring gain in the prior period. • Weighted average return on equity improved 1.41 percentage points to 9.09%.

Cash Flow and Balance Sheet • Net operating cash inflow decreased 29.28% to RMB1.42 billion. • Total assets expanded 2.43% to RMB15.34 billion, while net assets attributable to shareholders grew 4.21% to RMB12.40 billion.

Dividend Proposal Tasly Pharmaceutical’s board proposes a cash dividend of RMB1 (tax inclusive) for every 10 shares, subject to approval at the forthcoming 2025 annual general meeting.

The disclosed numbers are prepared under PRC GAAP and relate solely to Tasly Pharmaceutical, which is consolidated into China Resources Pharmaceutical’s results. Shareholders may refer to the full FY2025 annual report published on the Shanghai Stock Exchange for additional details.